SAN FRANCISCO — Middle-aged patients with impaired glucose tolerance (IGT) who can delay their progression to type 2 diabetes by 6 years — usually by making lifestyle changes — have a lower risk of diabetes-related complications when they are in their 70s, Asian researchers report.  

Guangwei Li,

...

Prediabetes in Older Adults: Who Will Get Diabetes?

Body weight, systolic blood pressure, and cardiovascular disease are key factors, study found

Of 981 adults ages 60 or older with prediabetes who were followed for 12 years, 204 (22%) reverted to normoglycemia and 119 (13%) developed diabetes,

...

SAN FRANCISCO -- Interventions intended to boost β-cell function during active treatment did not lead to persistent benefits after treatment withdrawal in type 2 diabetes, a researcher reported here.

In a four-armed intervention study of adults with impaired glucose tolerance or newly diagnosed

...

PREVIEW Study Confirms Lifestyle Changes Can Prevent Type 2 Diabetes,

But Half Dropped Out of Study

PREVIEW is the largest randomized control trial (gold standard of clinical trials) to date on the prevention of type 2 diabetes in adults with prediabetes through diet and exercise. Participants

...

The MiniMed 780G is the next iteration of the 670G hybrid closed loop system. Improvements and new features include automatic correction boluses, Bluetooth connectivity, remote software updating, a time-in-range goal greater than 80%, and an adjustable target blood glucose level down to 100 mg/dl. It

...
Immunbehandling fördröjer typ 1-diabetesdiagnos hos personer med hög risk

Läkemedlet Teplizumab (anti-CD3) som riktar sig mot immunsystemet kan fördröja insjuknandet i typ 1-diabetes i två år hos barn och vuxna med hög risk, visar en ny studie från det forskarnätverket TrialNet. Resultaten
...
örsta resultat från observationsstudien CaReMe, baserad på registerdata från bland annat Sverige under åren 2007 till 2016, presenterades vid den amerikanska diabeteskongressen, ADA, den 9 juni. Studien har följt 645 180 personer med typ 2-diabetes som inte tidigare haft etablerad...

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C Gersteinet al 

ABSTRACT

Summary
Background

Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for

...

Abstract Hertzel C Gersteinet al

Summary
Background

Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c (HbA1c) concentrations.

We assessed the effect of the GLP-1

...

 

Pancreatic beta cells that do not produce sufficient insulin in people with type 2 diabetes (T2D) are not permanently damaged during the early stages of the disease and can be restored to normal function through the removal of excess fat in the cells, according to a study entitled “Remission of Type

...

 

SAN FRANCISCO — As automated insulindelivery is rapidly evolving, interchangeability between insulin pumps and sensors on the various platforms is emerging as a key component to moving the field forward.

Here at the American Diabetes Association (ADA) 2019 Scientific Sessions, many attendees who

...

Dr. Roy Beck on CGM Accuracy and Use: “The benefit is far exceeding the burden now.”

Jaeb Center’s Dr. Roy Beck provided a very positive overview of continuous glucose monitor (CGM) options in the US, covering the four available systems: Dexcom’s G6, Abbott’s FreeStyle Libre, Medtronic’s 

...

Terrifying Complications in 20 Year Olds With Type 2 Diabetes

SAN FRANCISCO — Young people who were diagnosed with type 2 diabetes in their early teens had an "alarming" high rate of diabetes-associated complications by the time they were in their mid-20s, in new research.

Moreover, among more

...
SAN FRANCISCO — Diabetologists in recent years have been forewarning people with newly diagnosed type 2 diabetes they have a progressive condition that will eventually require insulin therapy. But one expert believes his latest research supports a different approach.

"We can say, 'If you stay your...

The question about real-world evidence is no longer whether data collected during routine clinical processes can be useful, but rather, how can it best be used?

Mikhail Kosiborod, MD

Mikhail Kosiborod, MD

“In recent years we have several examples of large, international comparative effectiveness studies showing that on a

...

A pair of experts addressed about how intensive therapy should be to lower low-density lipoprotein (LDL) cholesterol during Friday’s session Is Very Aggressive Lowering of LDL Cholesterol Worthwhile? 

Steven E. Nissen MD, MACC

Steven E. Nissen, MD, MACC

Arguing in favor of aggressive therapy, Steven E. Nissen, MD, MACC,

...

Recent clinical trials studying the safety and efficacy of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with diabetes have created opportunities for collaboration between cardiologists, diabetologists, primary health and

...

SAN FRANCISCO — Vitamin D3 supplementation in people at high risk of developing diabetes but who did not have vitamin Dinsufficiency does not reduce the chances of developing the disease compared with placebo, the new results of a randomized, placebo-controlled trial show.

The findings from the

...

SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution

  1. Joseph I. Wolfsdorf1⇑ and 
  2. Robert E. Ratner2

Intensive insulin management is currently the only option for effective treatment of type 1 diabetes. Recent data from the T1D Exchange (T1DX) registry (1), which comprises leading U.S.

...
Patientorganisationer gör 
tummen ned för utredning
 

Läkemedelsutredningen lever inte upp till förväntningarna. Ett redan komplext system föreslås bli ännu mer svåröverskådligt. Det skriver företrädare för 16 patientorganisationer på SvD debatt i gårdagens tidning.Debattörerna anser att det är

...

What will Come Up and

to Look Out for at ADA 2019

The American Diabetes Association (ADA) 79th Scientific Sessions is right around the corner!

The biggest scientific diabetes conference of the year will take place in San Francisco, California from June 7-11!

Below is a preview of what we’re

...
 The treatment approach to type 2 diabetes should begin with an assessment of cardiovascular disease (CVD) status, other comorbidities, and patient preferences, according to a draft of the upcoming 2018 joint consensus statement from the American Diabetes Association (ADA) and European Association
...
Posters. Absteacts
 
FreeStyle Libre™ Use for Self-Management of Diabetes in Teenagers and Young Adults
 
Author FIONA  CAMPBELL, JAN BOLINDER, Leeds, United Kingdom, Stockholm, Sweden

The challenges of caring for diabetes in teenagers and young adults are well known. We analyzed two research studies
...
The Pros and Cons of Gastric Bypass Surgery in Obese Individuals with Type 2 Diabetes—Nationwide, Matched, Observational Cohort
 
Oral presentation
The Author Group received 1000 US dollar from ADA at a meeting yesterday for excellent study and the statistical model
 
Study abstract 

Introduction:
Long-term effects
...
TEDDY Trial Struggles to Identify Environmental Triggers of Type 1 Diabetes
 
The TEDDY study (make a Google) hypothesized that there are “triggers” that cause a child with high-risk genes for type 1 diabetes to actually get type 1, based on the observation that not all children who are at higher risk
...